Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Oral semaglutide does not interact with any of the major cytochrome P450 isoforms, indicating a low likelihood for drug-drug interactions. Oral semaglutide does not appear to affect the metabolism of warfarin, however regular monitoring of INR is recommended for those on warfarin after starting the treatment. If your patient reported warfarin use in their screening questionnaire, we have asked them to arrange this. It is important that participants taking thyroxine continue to undergo regular checks of their thyroid function tests.

  • ASCEND PLUS (A Study of Cardiovascular Events iN Diabetes PLUS) is a randomised double-blind placebo-controlled trial sponsored by the University of Oxford.
  • ASCEND PLUS is registered with clinicaltrials.gov (NCT05441267) and ISRCTN (ISRCTN76193287).
  • The UTN universal trial number for ASCEND PLUS is U1111-1284-0262.
  • Protocol [PDF]